GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » EBITDA Margin %

Nextage Therapeutics (XTAE:NXTG) EBITDA Margin % : -209.12% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nextage Therapeutics's EBITDA for the six months ended in Dec. 2023 was ₪-1.49 Mil. Nextage Therapeutics's Revenue for the six months ended in Dec. 2023 was ₪0.71 Mil. Therefore, Nextage Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -209.12%.


Nextage Therapeutics EBITDA Margin % Historical Data

The historical data trend for Nextage Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics EBITDA Margin % Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -630.37 -8,308.90 -8,334.07 - -459.47

Nextage Therapeutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,638.78 - - -1,388.34 -209.12

Competitive Comparison of Nextage Therapeutics's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nextage Therapeutics's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's EBITDA Margin % falls into.



Nextage Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nextage Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.025/0.876
=-459.47 %

Nextage Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.491/0.713
=-209.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nextage Therapeutics  (XTAE:NXTG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Nextage Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nextage Therapeutics (XTAE:NXTG) Business Description

Traded in Other Exchanges
N/A
Address
Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines